[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 387
Citations 0
Comment & Response
August 28, 2013

Reductions in Funding for Medical Research

Author Affiliations
  • 1Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia
JAMA. 2013;310(8):855-856. doi:10.1001/jama.2013.170797

To the Editor Dr Emanuel1 ascribed much of the blame for increasing health care costs to biomedical research, and cited increasing costs as a major reason for the decrease in real dollars for NIH funding. He pointed out that the NIH must demonstrate its ability to lower costs. The true picture is far more complex.

First, Emanuel used bevacizumab as an example of an expensive, noncurative drug. Other examples of noncurative drugs that have had a major effect on health are statins and antiretrovirals. These drugs do not cure coronary artery disease or human immunodeficiency virus but do prolong life. Even the example that Emanuel cited as a triumph, the Hemophilus influenzae type B vaccine, could be seen as increasing costs because individuals saved by this vaccine could eventually develop expensive diseases as the population ages.

First Page Preview View Large
First page PDF preview
First page PDF preview
×